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OBJECTIVE—Impaired glucose counterregulation during hypo-
glycemia is well documented in patients with type 1 diabetes;
however, the molecular mechanisms underlying this defect
remain uncertain. We reported that the inhibitory neurotransmit-
ter g-aminobutyric acid (GABA), in a crucial glucose-sensing re-
gion within the brain, the ventromedial hypothalamus (VMH),
plays an important role in modulating the magnitude of the glu-
cagon and epinephrine responses to hypoglycemia and inves-
tigated whether VMH GABAergic tone is altered in diabetes
and therefore might contribute to defective counterregulatory
responses.
RESEARCH DESIGN AND METHODS—We used immuno-
blots to measure GAD65 protein (a rate-limiting enzyme in GABA
synthesis) and microdialysis to measure extracellular GABA lev-
els in the VMH of two diabetic rat models, the diabetic BB rat and
the streptozotocin (STZ)-induced diabetic rat, and compared
them with nondiabetic controls.
RESULTS—Both diabetic rat models exhibited an ~50% increase
in GAD65 protein as well as a twofold increase in VMH GABA
levels compared with controls under baseline conditions. More-
over, during hypoglycemia, VMH GABA levels did not change in
the diabetic animals, whereas they signiﬁcantly declined in non-
diabetic animals. As expected, glucagon responses were absent
and epinephrine responses were attenuated in diabetic rats com-
pared with their nondiabetic control counterparts. The defective
counterregulatory response in STZ-diabetic animals was restored
to normal with either local blockade of GABAA receptors or
knockdown of GAD65 in the VMH.
CONCLUSIONS—These data suggest that increased VMH
GABAergic inhibition is an important contributor to the absent
glucagon response to hypoglycemia and the development of
counterregulatory failure in type 1 diabetes. Diabetes 60:1582–
1589, 2011
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atrogenic severe hypoglycemia is the most serious
acute complication in insulin-treated diabetes, and it
remains the limiting factor in maintaining proper
glycemic control (1,2). The brain, and particularly
the ventromedial hypothalamus (VMH), plays a crucial role
in sensing hypoglycemia and initiating the physiological
counterregulatory responses that rapidly correct it (3–6),
namely the release of glucagon and epinpehrine (7). In
longstanding type 1 diabetes, however, these mechanisms
are either lost or become impaired, making these individ-
uals more susceptible to the threat of hypoglycemia (8).
Although the mechanism(s) underlying these defects have
not been identiﬁed, it has been postulated that impaired
glucose counterregulation in type 1 diabetes stems from
a number of factors. The ﬁrst of which is the simultaneous
loss of endogenous insulin secretion and, in association,
the capacity to release glucagon in response to hypogly-
cemia (9). The latter is thought to be the result of a number
of intra- and extrapancreatic factors, including the loss of
b-cells and thus the capacity to suppress the local release
of insulin (10–12), zinc (13,14), and the neurotransmitter
g-aminobutyric acid (GABA) (15) during hypoglycemia.
These factors together, when coupled with excessive ad-
ministration of exogenous insulin, act to suppress gluca-
gon release. Second, adaptations that occur within the
central and peripheral nervous system have been impli-
cated in the impaired glucagon as well as epinephrine
responses as well, including alterations in brain glucose
and monocarboxylic acid transport and metabolism, and
changes in neural innervation of the islet (16–23). The precise
mechanisms and the relative contributions of the many dis-
turbances in peripheral and central signals to counter-
regulatory failure in type 1 diabetes still are unclear.
Glucose and glucose deprivation have been shown to
alter GABA levels within the brain (24–27), but the evi-
dence for its role in regulating glucose counterregulation
remains somewhat controversial. Our laboratory reported
that GABA acts within the VMH to modulate the magnitude
of both the glucagon and epinephrine responses to hypo-
glycemia in nondiabetic rats (28). Subsequently, we dem-
onstrated that increased GABAergic tone in the VMH was
an important contributor to counterregulatory failure in
nondiabetic rats exposed to recurrent antecedent hypo-
glycemia (29). Studies in nondiabetic humans also have
shown that activation of GABAA receptors with systemic
delivery of the benzodiazepine analog, alprazolam, reduces
counterregulatory and neuroendocrine responses to hy-
poglycemia in primates and healthy human subjects (30–
32). Conversely, administration of modaﬁnil to healthy
human subjects to lower brain GABA concentrations was
reported to improve adrenergic sensitivity and some
aspects of cognitive function during hypoglycemia but did
not signiﬁcantly affect counterregulatory hormone release
(33).
The current study was undertaken to investigate
whether GABA inhibitory tone is increased in the VMH in
two rodent models of type 1 diabetes and whether GABA
contributes to defective counterregulation during hypo-
glycemia in diabetes. Our data suggest, for the ﬁrst time,
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ORIGINAL ARTICLEthat increased hypothalamic GABAergic neurotransmis-
sion plays a signiﬁcant role in the loss of the glucagon
response as well as the impairment of epinephrine release
seen in rats with type 1 diabetes during acute hypoglyce-
mia and that these counterregulatory defects are reversed
by speciﬁcally reducing excessive GABA tone in the VMH.
RESEARCH DESIGN AND METHODS
All rats started with a body weight of ~300 g and were individually housed in
the Yale Animal Resources Center in temperature-controlled (22–23°C) and
humidity-controlled rooms. The animals were fed a standard rodent diet
(Agway Prolab 3000, Syracuse, NY) and water ad libitum and were acclima-
tized to handling and a 12-h light cycle (lights on between 0700 h and 1900 h)
before experimental manipulation. Principles of laboratory animal care were
followed, and experimental protocols were approved by the institutional ani-
mal care and use committee at Yale University.
BB diabetic rats. Diabetic BB/Wor rats (n = 6) were obtained from the
University of Massachusetts (Worcester, MA). Blood glucose levels were
monitored twice daily using a glucometer (Bayer Contour), and a single sub-
cutaneous injection of protamine zinc insulin was administered to maintain
plasma glucose concentrations between ~350 and 450 mg/dL. Once blood
glucose levels were stable within this range, the BB rats were maintained at
this target for a period of 2 weeks before being studied. The insulin dose was
reduced on the day prior to the study to prevent unexpected hypoglycemia
during the fasting period.
Streptozotocin-induced diabetic rats. Diabetes was induced in male SD rats
(~300 g;Charles River) using a single intraperitoneal injection of streptozotocin
(STZ; 65 mg/kg in citrate buffer). Nondiabetic control animals received a single
intraperitoneal injection of an equivalent volume of citrate buffer. A 10% glucose
solution was provided in the drinking water for the ﬁrst 24 h to prevent hypo-
glycemia. STZ-induced diabetic animals were not insulin treated, and the con-
dition was maintained for a total of 2 weeks before the animals were studied.
Blood glucose was monitored twice daily with a glucometer to ensure adequate
hyperglycemia (.250 mg/dL) in our diabetic animals. Nondiabetic SD rats
served as controls.
Surgery. Approximately 8–10 days prior to the experiment, the animals un-
derwent aseptic surgery to have vascular catheters implanted into the left
carotid artery for blood sampling and right jugular vein for infusion. These
catheters were tunneled subcutaneously and exteriorized at the back of the
neck. Subsequently, the animals were placed into a stereotaxic frame (David
Kopf Instruments, Tujunga, CA) and bilateral stainless steel guide cannulas
(Eicom, Kyoto, Japan) for microdialysis and/or microinjection (from bregma:
VMH: 2.6 mm posterior, 3.8 mm lateral, and 8.9 mm ventral at an angle of 16°;
paraventricular nucleus [PVN]: 1.5 mm posterior, 3.8 mm lateral, and 7.9 mm
ventral at an angle of 22°), which were bilaterally inserted into the brain and
secured in place with screws and dental acrylic. These coordinates position
the 1-mm microdialysis probes into the ventrolateral portion of the VMH. The
animals were then allowed to recover for ~1 week in their home cages before
being studied.
Microdialysis. Animals were fasted overnight in the microdialysis cages to
allow sufﬁcient time for acclimation. The next day, the animals were connected
to infusion pumps and bilateral microdialysis/microinjection probes were
inserted. Artiﬁcial extracellular ﬂuid (aECF) was perfused through the
microdialysis probes at a constant rate of 1.5 mL/min for 2.5–3 h to allow GABA
levels to stabilize prior to the start of the microdialysate and baseline blood
sample collection. Microdialysate samples were then collected at 10-min
intervals for the duration of the study.
Glucose clamp. Following a baseline collection period of 35 min, a constant
insulin (50 mU/kg/min) and variable 50% dextrose infusion were used to induce
baseline euglycemia (115 6 10 mg/dL) for at least 30 min. Once plasma glucose
levels were stable, blood samples were taken at this time to assess plasma
hormone concentrations during hyperinsulinemic-euglycemia, and, sub-
sequently, the rats were microinjected with 0.1 mL of aECF vehicle over the
course of 1 min using a CMA 402 syringe pump (CMA Microdialysis, North
Chelmsford, MA). This microinjection protocol minimizes the spread of the
compound and has been shown to localize the injection to the ventromedial
nucleus (33). To determine whether the counterregulatory defect could be
reversed in diabetic rats by blocking GABAergic inhibition in the VMH, we
bilaterally microinjected the GABAA receptor antagonist, bicuculline methio-
dide (BIC; 12.5 pmoL per side), into the VMH of one subgroup of STZ-induced
diabetic animals just prior to the induction of hypoglycemia. The dose of BIC
used here is a subconvulsive dose determined in a previously described pilot
study (28). Speciﬁcity of the response to VMH BIC injection was assessed in
a subgroup of animals that received a similar injection of BIC into the PVN of
the hypothalamus. Following microinjection, the glucose infusion rate was
decreased and plasma glucose levels were lowered and maintained at ~50 6 5
mg/dL for 90 min. Blood samples were collected at 30-min intervals through-
out the hypoglycemic clamp portion of the study for measurement of plasma
glucagon and catecholamine responses and at the end of the study for plasma
insulin concentrations. Following each sample collection, the erythrocytes
were resuspended in an equivalent volume of artiﬁcial plasma (34) and rein-
fused back into the animal to prevent volume depletion and anemia. At the end
of the study, following collection of the ﬁnal blood and microdialysate sam-
ples, the animals were killed with an overdose of sodium pentobarbital, and
the brains were removed and frozen on dry ice. Subsequently, accuracy of
probe placement was determined histologically by visual inspection of coronal
brain sections. Only data obtained from those animals with correctly posi-
tioned microdialysis probes were analyzed.
GAD65 knockdown. To address the issue of pharmacological speciﬁcity with
the use of bicuculline, we used a gene knockdown approach to locally decrease
the expression of the rate-limiting enzyme in GABA synthesis, GAD65,i nt h e
VMH of STZ-induced diabetic rats. In two subgroups of STZ-induced diabetic
rats, an adeno-associated virus (AAV) that expressed either a short-hairpin
RNA (shRNA) against GAD65 or a scrambled RNA sequence that does not
adhere to any known sequences listed in Genbank were microinjected into the
VMH 1 week after the induction of diabetes at a rate of 0.1 mL/min for 15 min.
This method of delivery limits the spread of the virus to the VMH (35). Non-
diabetic control animals received an injection of the AAV with the scrambled
RNA sequence. One week after microinjection of the AAV, the animals were
subjected to a hyperinsulinemic-euglycemic-hypoglycemic clamp, as de-
scribed above, to assess counterregulatory hormone proﬁles. The shRNA
sequence, which has 100% homology with both rat and mouse GAD65,i s
59-TCTGGTTTGTACCTCCTAGTT-39 and that for the scrambled sequence is
59-GGAATCTCATTCGATGCATAC-39.
Hormone and microdialysate analysis. Plasma catecholamine concen-
trations were analyzed by high-performance liquid chromatography, using
electrochemical detection, whereas plasma hormone concentrations were
determined using commercially available radioimmunoassay kits. VMH GABA
concentrations from microdialysate samples were determined using liquid
chromatography–tandem mass spectrometry after butylation, as previously
described (36).
Immunoblot analysis. Frozen tissue micropunches from the VMH (~2.12 to 2
3.60 mm from bregma) were homogenized in 30 mL of lysis buffer (20 mmol/L
HEPES, 50 mmol/L glycerol-2-phosphate, 2 mmol/L EGTA, 1 mmol/L dithio-
threitol, 10 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1% Triton X-100,
and 10% glycerol), using a plastic pestle and ultrasonicator. Protein content
was assessed with the Bradford protein assay (BioRad). Equal amounts of
protein (15 mg) were resolved under reducing conditions in a 4–20% SDS-
polyacrylamide gradient gel. Protein samples were then transferred onto
nitrocellulose membranes. Success of the protein transfer was assessed by ex-
posure of the nitrocellulose membranes to Ponceau S solution. Subsequently,
the membranes were thoroughly washed prior to being soaked in 5% blocking
solution for 1 h at room temperature. The membranes were then washed with
0.01 mol/L PBS, incubated with primary antibodies directed against GAD and
b-actin, washed with PBS, and incubated with an appropriate secondary an-
tibody conjugated to peroxidase. Following incubation with the secondary
antibody, the membranes were washed with PBS and immersed into chemi-
luminescent reagent. The membranes were then exposed to Kodak X-OMAT
ﬁlm. Film analysis was undertaken using a computerized image analysis sys-
tem running Kodak Digital Science One D software. Protein levels are
expressed as a ratio of GAD and b-actin in order to correct for differences in
loading and transfer.
Statistical analysis. Treatment effects were analyzed using one- or two-way
ANOVA for independent or repeated measures, as appropriate, followed by
post hoc analysis using the Statistica suite of analytical software for personal
computers by StatSoft. P , 0.05 was set as the criterion for statistical signif-
icance.
RESULTS
Table 1 summarizes baseline levels of glucose and glu-
coregulatory hormones. Diabetic rats exhibited marked
elevations in plasma glucose levels. Despite the presence
of hyperglycemia in the diabetic animals, fasting plasma
insulin concentrations were inappropriately reduced. In-
sulin was almost completely absent in the BB rats and
lower, albeit not signiﬁcantly, in STZ-induced diabetic rats.
Plasma glucagon levels were more than twofold higher
in BB diabetic rats but not signiﬁcantly increased in the
STZ-induced diabetic animals compared with nondiabetic
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icantly between control and diabetic rats.
Under basal conditions, VMH GAD65 protein levels were
elevated by ~50% in both of our diabetic animal models
(Fig. 1A). No differences were observed in GAD67 protein
levels between control and diabetic animals (Fig. 1B).
Figure 2A shows a schematic of our experimental pro-
tocol. Plasma glucose concentrations of diabetic animals
were signiﬁcantly higher than their nondiabetic counter-
parts (Fig. 2B) at the beginning of the study. After the start
of the insulin infusion, plasma glucose levels of nondiabetic
animals were maintained at euglycemia, whereas those of
the diabetic animals were gradually lowered over the
course of 2 h to match the euglycemic levels in nondiabetic
controls. Stable euglycemia was then maintained for 30 min
in all animals prior to microinjection and the induction of
hypoglycemia. Average plasma glucose levels during the
hypoglycemic plateau were similar between all of the
treatment groups.
The increase in GAD65 corresponded with an approxi-
mate doubling of baseline interstitial GABA levels in the
VMH of diabetic animals (Fig. 3A). During hyperinsulinemic-
euglycemia, extracellular GABA levels did not change
from their respective baseline levels. As expected, in re-
sponse to hypoglycemia, VMH GABA levels decreased
by ~50% in nondiabetic animals. This drop was associated
with activation of both the glucagon and epinephrine
responses (Fig. 3B and C, respectively). In contrast, VMH
GABA levels in both diabetic animal models did not fall
from their high baseline concentrations in response to
TABLE 1
Baseline plasma glucose and hormone concentrations of non-
diabetic controls, BB diabetic rats, STZ-induced diabetic rats,
and STZ-induced diabetic rats receiving BIC into the VMH
Control
rats BB rats STZ rats
STZ+BIC
rats
Glucose (mg/dL) 128 6 1 589 6 64* 293 6 35* 274 6 56*
Glucagon (pg/mL) 38 6 68 9 6 8† 59 6 14 41 6 7
Insulin (mU/mL) 14 6 21 6 1¶ 8 6 39 6 4
Epinephrine
(pg/mL) 64 6 20 51 6 31 45 6 12 83 6 25
Data are presented as means 6 SE. *P , 0.03 vs. control. †P , 0.01
vs. control. ¶P , 0.003 vs. control.
FIG. 1. Representative image and densitometric analyses of immuno-
blots for GAD65 (A) and GAD67 (B) protein in the VMH of control (n =
6), diabetic BB (n = 3), and STZ-induced diabetic (n = 6) rats. Data are
presented as relative optical density (R.O.D.) expressed as a ratio over
b-actin levels. Results are presented as means 6 SE. *P < 0.001 vs.
control.
FIG. 2. A: Schematic diagram showing stepped hyperinsulinemic-
euglycemic-hypoglycemic clamp protocol. Microdialysate samples were
continuously collected throughout the study. Constant insulin (50
mU/kg/min) and variable glucose infusions were started at 21509 and
continued for the remainder of the study. Plasma glucose concentrations
of diabetic animals (dotted line) were lowered to match euglycemic levels
(115 6 10 mg/dL) in nondiabetic animals for 30 min prior to microin-
jection at 09 and induction of hypoglycemia (50 6 5 mg/dL). B: Plasma
glucose concentrations of nondiabetic controls (Control; n = 6), di-
abetic BB rats (BB Rat; n = 3), STZ-induced diabetic rats (STZ; n =6 ) ,
and STZ-induced diabetic rats microinjected with the GABAA receptor an-
tagonist (STZ + BIC; n = 6) under baseline conditions (□), during hyper-
insulinemic-euglycemia (▨), and during hyperinsulinemic-hypoglycemia
(■). Results are presented as means 6 SE. *P < 0.000 vs. Control at
baseline; ¶P < 0.001 vs. Control at baseline.
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glucagon and an attenuated epinephrine response.
To assess whether increased inhibitory GABAergic
output is responsible for the impairment of counter-
regulatory hormone release, we microinjected the GABAA
receptor antagonist, BIC, into the VMH of STZ-induced
diabetic animals to block postsynaptic GABAA receptors
prior to the induction of hypoglycemia. Administration of
bicuculline restored both the glucagon and epinephrine
responses to normal in diabetic animals, despite the per-
sistence of elevated GABA levels in the VMH (Fig. 3). To
establish whether the effects of the bicuculline injection
were speciﬁc to the VMH, we microinjected bicuculline
into another region of the brain that also expresses GABAA
receptors, the PVN of the hypothalamus, and measured the
counterregulatory responses to hypoglycemia. In this study,
we noted that blockade of GABAA receptors in the PVN did
not affect the release of glucagon or epinephrine in either
nondiabetic or STZ-induced diabetic animals (Table 2).
Using an alternative and more speciﬁc approach to test
our hypothesis, we administered an AAV expressing
a shRNA against GAD65 into the VMH of STZ-induced
FIG. 3. A: Extracellular GABA concentrations in the VMH of nondiabetic controls (Control; n =6 ;○, solid line), diabetic BB rats (BB Rat; n =3 ;●,
solid line), STZ-induced diabetic rats (STZ; n =6 ;△, dotted line), and STZ-induced diabetic rats microinjected with the GABAA receptor an-
tagonist (STZ + BIC; n =6 ;▲, dotted line) under baseline (Basal), hyperinsulinemic-euglycemic (2309 to 09) and hyperinsulinemic-hypoglycemic
(409 to 809) conditions. B and C: Plasma glucagon and epinephrine concentrations under baseline (Basal), hyperinsulinemic-euglycemic (09), and
hyperinsulinemic-hypoglycemic (309 to 909) conditions. Data are presented as means 6 SE. *P < 0.05 vs. Control; †P < 0.05 vs. Control at baseline;
‡P < 0.05 vs. Control at 309.
TABLE 2
Change in plasma glucagon and epinephrine concentrations from
baseline concentrations in nondiabetic controls and STZ-induced
diabetic animals during a hypoglycemic glucose clamp (n = 5 per
group)
DGlucagon (pg/mL) DEpinephrine (pg/mL)
Control 141 6 33 4,166 6 430
Control + BIC 163 6 7 3,657 6 258
STZ 47 6 17* 1,520 6 195†
STZ + BIC 35 6 14* 1,186 6 328†
Data are presented as means 6 SE. Animals from each treatment
group were microinjected with either artiﬁcial extracellular ﬂuid or
the GABAA receptor antagonist, BIC, into the PVN. *P , 0.05 vs.
control. †P , 0.001 vs. control.
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The GAD65 shRNA lowered GAD65 protein levels in STZ-
induced rats with diabetes to normal levels, whereas the
scrambled shRNA had no signiﬁcant effect (Fig. 4). Ad-
ministration of neither the AAV expressing GAD65 shRNA
nor the scrambled shRNA had any signiﬁcant effect on
baseline plasma glucose concentrations compared with
control and STZ animals in the above study (Fig. 5).
However, the reduction in GAD65 expression resulted in
normalization of baseline extracellular GABA levels in
STZ-induced diabetic animals and, more importantly, re-
stored the drop in VMH GABA levels during hypoglycemia
(Fig. 6A). Knockdown of GAD65 in the VMH of STZ-
induced diabetic rats also restored the glucagon and
epinephrine responses to hypoglycemia (Fig. 6B and C,
respectively).
DISCUSSION
Counterregulatory failure in type 1 diabetes is a well-
documented phenomenon. The mechanisms responsible
for this defect, however, are not well understood. In pre-
vious studies, we showed that inhibitory GABAergic neu-
rotransmission in the VMH is important for modulating the
magnitude of glucose counterregulatory responses to an
acute bout of hypoglycemia in rats (28). We subsequently
reported that marked increases in GABAergic inhibitory
neurotransmission within the VMH play an important role
in the development of counterregulatory failure following
antecedent exposure to hypoglycemia in nondiabetic
rodents (29). In the current study, we show that a similar
mechanism may be operating in type 1 diabetic rodents
and could be a new unrecognized factor contributing to
the development of counterregulatory failure, which is
a major complication of the disease.
In the ﬁrst set of studies, we characterized the GABA
defect in two different rodent models of type 1 diabetes,
the spontaneously diabetic BB rat and the STZ-induced
diabetic rats. We observed that under baseline conditions,
both diabetic animal models exhibited increased GAD65
protein levels in the VMH, and this was corroborated by
a biological marker, the doubling in extracellular GABA
levels. The fact that the data are so remarkably similar
between these two different animal models of type 1 di-
abetes suggests that it is likely the diabetic condition itself,
and not the potentially toxic side effects of STZ, that is
responsible for increasing GABA output within the VMH.
Interestingly, no differences were observed with GAD67
protein in the VMH. Our data are consistent with pre-
viously published reports showing increased GABA tone in
the VMH of STZ-induced diabetic animals. Beverly et al.
(37,38) reported increased GABA shunt and GAD activity
in the VMH of STZ-induced diabetic rats, whereas Ohtani
et al. (39) used microdialysis to show that GABA levels
were elevated in the VMH of STZ-induced diabetic rats.
Taken together, these data suggest that diabetes raises
GABA output in the VMH at least in part by increasing
GABA synthesis and release. Although microdialysis pro-
vides an assessment of net changes in extracellular GABA
levels within the VMH, it does not allow us to speciﬁcally
identify the source of GABA. Although the majority of
GABA is thought to be of neuronal origin, astrocytically
derived GABA also has been reported, but its con-
tributions to the VMH interstitial pool and to glucose
sensing have not been established (40,41).
In response to a hypoglycemic challenge, VMH GABA
levels decrease in our control animals, and this corre-
sponded with activation of both the glucagon and epi-
nephrine responses. In contrast, VMH GABA levels
remained elevated during hypoglycemia in both of our
diabetic animal models, and this was associated with ab-
sent glucagon and attenuated epinephrine responses,
establishing for the ﬁrst time a link between increased
inhibitory neurotransmission in the VMH and defective
glucose counterregulatory responses in diabetes.
Interestingly, we noted that under hyperinsulinemic-
euglycemic conditions, VMH GABA levels in nondiabetic
animals did not change signiﬁcantly from baseline levels.
This implies that in normal animals, the release of GABA
already may have reached a physiological ceiling under
conditions of euglycemia, and the addition of insulin may
not provide additional stimulation for GABA release. This
is consistent with data from our recent study showing
that the administration of increasing doses of glucose into
the VMH during peripherally induced hypoglycemia dose-
dependently raises extracellular GABA levels. These GABA
levels continue to increase until euglycemic levels are
reached, at which point they plateau at normal baseline
levels (42). Raising VMH glucose concentrations above
euglycemic levels does not increase VMH GABA levels fur-
ther. In the case of the diabetic animals, the fact that GABA
levels also remain high under hyperinsulinemic-euglycemic
conditions suggests that factors apart from glucose and in-
sulin may be responsible for raising GABAergic output in the
VMH.
Although most of GABAergic neuronal cell bodies reside
in the perimeter of the ventromedial nucleus, we have
shown that a signiﬁcant number of GAD65-positive nerve
terminals exist within the body of the VMH and that
a subpopulation of these neurons coexpress ATP-sensitive
K
+ channels (42). More importantly, this subpopulation of
VMH GABAergic neurons responds to local changes in
glucose levels. What this suggests is that these neurons in
FIG. 4. In vivo validation of GAD65 knockdown in STZ-induced diabetic
animals. Representative image showing b-actin and GAD65 protein
bands. Graph shows densitometric analyses of immunoblots for GAD65
protein in the VMH of controls with the scrambled shRNA (n = 4), STZ-
induced diabetic rats with aECF (n = 4), STZ-induced diabetic rats with
the scrambled shRNA (n = 4), and STZ-induced diabetic rats with the
GAD65 shRNA (n = 4), 1 week after AAV microinjection. Data are rep-
resented as relative optical density (R.O.D.) expressed as a ratio over
b-actin levels. Results are presented as means 6 SE. *P < 0.001 vs.
Control + Scrambled shRNA.
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selves or that they may form synapses with other glucose-
sensing neurons to modulate activity of those neurons as
part of the glucose-sensing network that regulates the
counterregulatory responses to hypoglycemia. In diabetes,
increased activation of GABAergic tone may then prevent
this network from initiating an appropriate response.
Having demonstrated that diabetes increases GABA
levels in the VMH and that this was associated with an
impaired counterregulatory response, we examined whether
increased GABAergic neurotransmission in the VMH con-
tributed to suppression of counterregulatory responses
to hypoglycemia in diabetic animals using two parallel
approaches. In the ﬁrst approach, we microinjected BIC
into the VMH of STZ-induced diabetic rats to locally block
postsynaptic GABAA receptors prior to the induction of
hypoglycemia. This treatment completely restored both
the glucagon and epinephrine defects in the diabetic ani-
mals, suggesting that increased GABAergic output in the
VMH contributes signiﬁcantly to attenuating the counter-
regulatory responses to hypoglycemia. The inhibitory
effects on glucagon and epinephrine appear to be speciﬁc
to GABAergic neurotransmission in the VMH because mi-
croinjection of BIC into a neighboring nucleus, the PVN,
failed to restore the counterregulatory defects in diabetic
animals.
To address issues associated with the speciﬁcity of BIC,
we performed a second series of studies in which we locally
administered an AAV that expressed either an shRNA
against GAD65 to locally knock down GAD65 expression or
one that expressed a nonspeciﬁc RNA sequence into the
VMH of STZ-induced diabetic animals. Administration of the
scrambled shRNA AAV did not have any demonstrable
effects on VMH GAD65 expression, extracellular GABA
levels, plasma glucose, or counterregulatory hormone re-
lease. Nondiabetic control animals receiving the scrambled
shRNA AAV exhibited the expected fall in baseline VMH
GABA levels and activation of the counterregulatory re-
sponse, whereas STZ-induced diabetic rats injected with the
scrambled shRNA AAV showed the expected high VMH
GABA levels and impaired counterregulatory responses to
hypoglycemia. In stark contrast, when the high VMH GAD65
levels in STZ animals were knocked down into the normal
r a n g eu s i n gaG A D 65 shRNA AAV, we not only brought
baseline GABA levels back down to normal, but, perhaps
more importantly, we also restored the drop in VMH GABA
concentrations during hypoglycemia. Knockdown of GAD65
in the VMH restored both the glucagon and epinephrine
responses to normal in the STZ-induced diabetic rats. This
suggests that 1) a sustained increase in VMH GABAergic
inhibition plays a key role in suppressing the glucagon and
epinephrine responses to hypoglycemia in diabetes and 2)
although the ability to decrease VMH GABAergic tone in
response to a hypoglycemic challenge still may be present
in diabetes, as evidenced by knockdown of GAD65,i ti st h e
abundant overproduction of GABA (most likely stemming
from higher GAD65 levels) that prevents GABA levels from
dropping below a critical threshold for full activation of
counterregulatory responses. This observation underscores
the importance of the role of the VMH to counterregulatory
failure in type 1 diabetes. Although most studies suggest
that the loss of the glucagon response to hypoglycemia in
type 1 diabetes is mediated through peripheral mechanisms,
including the loss of intraislet factors (10,11,13–15,43) as
well as sympathetic innervations to the a-cell (20), less at-
tention has been given to the role of the brain in this regard.
We previously reported that activation of the fuel sensor,
AMP kinase, in the VMH of BB rats can improve glucagon
responses to hypoglycemia (44), and the current data
demonstrate a similar restoration in two different models of
b-cell injury (and insulin insufﬁciency) by modulating
GABAergic neurotransmission in the VMH. These observa-
tions suggest that alterations in the capacity of the VMH,
a key glucose-sensing brain region, to recognize fuel deﬁcit
may contribute signiﬁcantly to the glucagon defect in di-
abetes as well. Thus, the VMH may play a greater role in
counterregulatory failure in diabetes than previously ap-
preciated.
Of particular interest is the fact that the data are re-
markably similar to what we observed in animals with
antecedent hypoglycemia. In both instances, we saw
increases in VMH GABAergic output that was associated
with impairments in the counterregulatory responses
and improvements in these responses with GABAergic
blockade. The fact that these two different conditions can
lead to similar changes in the central nervous system and
FIG. 5. Plasma glucose concentrations of nondiabetic control rats injected with the scrambled shRNA AAV (Control + Scrambled shRNA; n =6 ) ,
STZ-induced diabetic rat injected with the scrambled shRNA AAV (STZ + Scrambled shRNA; n = 6), and STZ-induced diabetic rat injected with
the GAD65 shRNA AAV (STZ + GAD65 shRNA; n = 6) under baseline conditions (□), during hyperinsulinemic-euglycemia (▨), and during
hyperinsulinemic-hypoglycemia (■). Results presented as means 6 SE. *P < 0.001 vs. Control at baseline.
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though the mechanism responsible is uncertain, this ﬁnd-
ing suggests that a common adaptation within the central
nervous system may occur in both of these conditions
that acts to increase GAD65 expression and GABA output
in the VMH that in turn contribute to counterregulatory
failure.
We conclude that diabetes leads to increased GAD65
expression in the VMH with resulting increases in local
GABA concentrations in this critical brain glucose-sensing
region. In addition, we have shown, using two parallel
approaches, that when GABA tone in the VMH is lowered
in STZ-induced diabetic animals, either pharmacologically
or genetically, we are able to restore the absent glucagon
response and also restore the impaired epinephrine re-
sponse to normal. Thus, uncontrolled or poorly controlled
type 1 diabetes increases GABAergic tone in the VMH.
Although the speciﬁc mechanisms responsible for these
changes in the synthesis and release of the inhibitory
neurotransmitter, GABA, remain to be established, they
appear to contribute, at least in part, to defective glucose
counterregulation in diabetes and thus be a therapeutic
target for diminishing the risk of this serious complication
of insulin treatment.
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